Skyrizi contains risankizumab-rzaa, an IL-23 antagonist. It binds to the p19 subunit of the IL-23 protein, inhibiting its interaction with the IL-23 receptor. This helps reduce inflammation by preventing the release of pro-inflammatory cytokines and chemokines, thereby improving symptoms associated with psoriasis, psoriatic arthritis, and Crohn’s disease.
Alert: Order your 3-month supply by October 12 to help avoid potential customs delays.
Get Semaglutide for $184 or Ozempic for $329
